European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised

Submitted by Anonymous (not verified) on 5 August 2026 - 11:40

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 5 August 2026 - 11:26

Human medicines European public assessment report (EPAR): Vantobra (previously Tobramycin PARI), tobramycin, Date of authorisation: 18/02/2019, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 5 August 2026 - 10:55

Human medicines European public assessment report (EPAR): Kisqali, ribociclib, Date of authorisation: 22/08/2017, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Loqtorzi, toripalimab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 4 August 2026 - 16:38

Human medicines European public assessment report (EPAR): Loqtorzi, toripalimab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Silapo, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 18, Status: Authorised

Submitted by Anonymous (not verified) on 4 August 2026 - 16:32

Human medicines European public assessment report (EPAR): Silapo, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Elmiron, pentosan polysulfate sodium, Date of authorisation: 02/06/2017, Revision: 15, Status: Authorised

Submitted by Anonymous (not verified) on 4 August 2026 - 16:20

Human medicines European public assessment report (EPAR): Elmiron, pentosan polysulfate sodium, Date of authorisation: 02/06/2017, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 4 August 2026 - 16:00

Human medicines European public assessment report (EPAR): Obodence, denosumab, Date of authorisation: 12/02/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 4 August 2026 - 15:50

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 16, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More